Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:age |
adolescents
adults |
| gptkbp:approvalYear |
2021
|
| gptkbp:brand |
gptkb:NVX-CoV2373
|
| gptkbp:composition |
recombinant spike protein
|
| gptkbp:containsAdjuvant |
gptkb:Matrix-M
|
| gptkbp:countryOfOperation |
gptkb:India
|
| gptkbp:developedBy |
gptkb:Novavax
|
| gptkbp:emergencyServices |
gptkb:India
|
| gptkbp:form |
two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Covovax
|
| gptkbp:indication |
prevention of COVID-19
|
| gptkbp:intervalBetweenDoses |
3 weeks
|
| gptkbp:manufacturer |
gptkb:Serum_Institute_of_India
|
| gptkbp:marketedAs |
gptkb:Serum_Institute_of_India
|
| gptkbp:regulates |
gptkb:Drugs_Controller_General_of_India
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
fatigue headache muscle pain injection site pain |
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:type |
protein subunit vaccine
|
| gptkbp:WHOEmergencyUseListing |
yes
|
| gptkbp:bfsParent |
gptkb:COVID-19
|
| gptkbp:bfsLayer |
4
|